Pfizer to complete Hospira purchase in early September

SHARE Pfizer to complete Hospira purchase in early September
SHARE Pfizer to complete Hospira purchase in early September

NEW YORK — Drugmaker Pfizer says it’s received the final regulatory approvals for its $15.23 billion purchase of Lake Forest-based Hospira, a maker of injectable drug and infusion devices, and says the deal will close in early September.

The New York company said Monday regulators in the U.S. and Brazil cleared the deal. European Union regulators approved it earlier this month, as did antitrust agencies in Canada and Australia.

Pfizer said the Federal Trade Commission ordered it to sell four drugs in order to preserve competition. The products are a chemotherapy drug, an antibacterial drug, an antifungal drug, and a drug used to prevent liver damage after acetaminophen overdoses.

Pfizer Inc., the world’s second-largest drug company in terms of revenue, makes drugs including the pain and arthritis treatment Celebrex, Prevnar pneumococcal vaccines, and fibromyalgia treatment Lyrica. It agreed to buy Hospira Inc. in February. The deal is intended to strengthen Pfizer’s position in the growing market for biosimilars, which are cheaper versions of biologic drugs. Pfizer said it will help expand Hospira’s reach to Europe and key emerging markets, as the company’s products are now mostly sold in the U.S.

The deal values Hospira at $90 per share.

The Latest
One of the wounded, a 32-year-old man, was driving down the street when he was struck by gunfire, police said.
The 34-year-old was crossing the street just before 8:30 p.m. in the 2900 block of West Columbus Avenue when she was struck by a black SUV.
“That’s where you build fandom, grow revenue, and that’s where all the players will benefit versus adding a roster spot here and there.”
Reflecting on one of the most iconic photos of his presidency, former President Obama said, “I think this picture embodied one of the hopes that I had when I first started running for office.”